Synergy Pharmaceuticals (SGYP) Releases Earnings Results, Misses Expectations By $0.01 EPS

Synergy Pharmaceuticals (NASDAQ:SGYP) released its earnings results on Thursday. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01), MarketWatch Earnings reports. The firm had revenue of $11.11 million for the quarter, compared to analyst estimates of $15.65 million.

SGYP traded down $0.09 on Friday, reaching $0.36. 9,599,730 shares of the company’s stock were exchanged, compared to its average volume of 7,622,059. The firm has a market capitalization of $114.13 million, a PE ratio of -0.35 and a beta of 2.38. Synergy Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $3.10.

A number of analysts have recently commented on the stock. BTIG Research cut shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, October 26th. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Synergy Pharmaceuticals in a research note on Tuesday, August 7th. Canaccord Genuity cut shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 26th. Zacks Investment Research lowered shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 10th. Finally, BidaskClub lowered shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $8.17.

COPYRIGHT VIOLATION WARNING: “Synergy Pharmaceuticals (SGYP) Releases Earnings Results, Misses Expectations By $0.01 EPS” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.thestockobserver.com/2018/11/10/synergy-pharmaceuticals-sgyp-releases-earnings-results-misses-expectations-by-0-01-eps.html.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Recommended Story: Relative Strength Index

Earnings History for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply